The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Qu, Xu Dong ^a   Chen, Cheng Shi ^a   Wang, Jian Hua ^a   Yan, Zhi ping ^a   Chen, Jie min ^a   Gong, Gao quan ^a   Liu, Qin xin ^a   Luo, Jian jun ^a   Liu, Lin xiao ^a   Liu, Rong ^a   Qian, Sheng ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; FLUOROURACIL; OXALIPLATIN; SORAFENIB;

ABDOMINAL TENDERNESS; ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAIR LOSS; HAND FOOT SYNDROME; HEARING LOSS; HEART LEFT VENTRICLE FAILURE; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SKIN MANIFESTATION; SURVIVAL TIME; SYMPTOM; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ADULT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84862502464     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-263     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Globle cancer statistics, 2002. CA Cancer J Clin 2005, 55(1):74-108.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
3. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000, 32:1224-1229. 10.1053/jhep.2000.20456, 11093728.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442. 10.1053/jhep.2003.50047, 12540794.
5. Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellularcarcinoma in a Japanese nationwide survey. Cancer 2004, 101:796-802. 10.1002/cncr.20426, 15305412.
6. Lo CM, Ngan H, Tso WK, Wong J, et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171. 10.1053/jhep.2002.33156, 11981766.
7. Dong-Jun Y, Kang Mo K, Young-Joo J, et al. Clinical outcome of 251 patients with extra hepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival inthese patients?. J Gastroenterol Hepatol 2011, 26:145-154. 10.1111/j.1440-1746.2010.06341.x, 21175808.
8. Llovet JM, Real MI, Montana X, et al. embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002, 359:1734-1739. 10.1016/S0140-6736(02)08649-X, 12049862.
9. Llovet JM, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739. 10.1016/S0140-6736(02)08649-X, 12049862.
10. Liapi E, Geschwind JF. Transcatheter Arterial Chemoembolization for Liver Cancer: Is It Time to Distinguish Conventional from drug-Eluting Chemoembolization?. Cardiovasc Intervent Radiol 2011, 34(1):37-49. 10.1007/s00270-010-0012-y, 21069333.
11. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma [J]. N Engl J Med 2008, 359(4):378-390. 10.1056/NEJMoa0708857, 18650514.
12. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double blind, placebo controlled trial[J]. Lancet Oncol 2009, 10(1):25-34. 10.1016/S1470-2045(08)70285-7, 19095497.
13. Esther A, Carlos V, Juan D, et al. Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma on the Waiting List for Orthotopic Liver Transplantation. Am J Roentgenol 2008, 190:1341-1348.
14. Livraghi T, Mäkisalo H. P.-D. Line3. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011, 100:22-29.
15. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009, 69(2):223-240. 10.2165/00003495-200969020-00006, 19228077.
16. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310. 10.1038/sj.onc.1210422, 17496923.
17. Pawlik-Timothy M, Reyes-Diane K, David-Cosgrove, et al. Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma, Journal of clinical oncology. J Clin Oncol 2011, 9:3960-3967.
18. Luo J, Yan Z, Liu Q, Qu X, Wang J. Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein. Journal of Vascular and Interventional Radiology 2011, 22(4):479-489. 10.1016/j.jvir.2010.11.029, 21463757.
19. Zhang XB, Wang JH, Yan ZP, Qian S, Liu R. Hepatocellular carcinoma invading the main portal vein: treatment with transcatheter arterial chemoembolization and portal vein stenting. Cardiovasc Intervent Radiol 2009, 32:52-61. 10.1007/s00270-008-9454-x, 18931871.